Advances in Autism Conference 2023
Thank you for your interest in the 27th Annual Advances in Autism conference. The conference took place on Tuesday, May 23. If you would like to watch the presentations, please visit the conference portal. If you would like more information, or to be added to the list to learn more about the Center and its events, please contact Sarah Lynch Sarah.Lynch@mssm.edu
About
Established in 1996, the conference brings together academic, parent, and community groups to participate in thoughtful and informative presentations. The goals of the event are to discuss recent advances in autism—the causes, symptoms, and current and future treatments.
The focus of the 2023 Advances in Autism Conference is Precision Medicine in Profound Autism.
International studies led by the Director of the Seaver Autism Center for Research and Treatment, Joseph D. Buxbaum, PhD, and colleagues, have identified more than 200 genes that, if changed, strongly contribute to autism. These discoveries also are showing that at least 25% of individuals with profound autism have genetic mutations.
Autism clinical researchers are now shifting their focus on treatments for autism. Rather than treating all autism as a single entity, we can now begin to look at genetically determined subtypes of autism, and consider treatments that are tailored to the genetic subtype. This approach, called precision medicine, has revolutionized cancer treatment, and will revolutionize the treatment of profound autism.
Attend the conference to learn how researchers are identifying genetic mutations in autism, how the mutations lead to biologically-determined subtypes of autism, and how preclinical research and clinical research are developing and testing new treatments for these subtypes. The interactions between academic scientists, families and advocacy groups, and industry partners will also be discussed, as precision medicine requires input from all these groups.
Online Conference Portal
Reserve Tickets Online
Agenda
10:30 10:40 AM - Opening Remarks
10:40 11:05 AM - Joseph D. Buxbaum, PhD
Genetics-First Approaches to Therapeutics in Autism
11:05 11:30 AM - Nael Nadif Kasri, PhD
Modelling Neurodevelopmental Disorders in a Dish
11:30 11:40 AM - 10-Minute Break
11:40 AM 12:05 PM - Bill Polvino, MD
New Drug Development in the Pharmaceutical Industry
12:05 12:30 PM - Rachel Groth, PhD
Building a Pharmaceutical Industry, Academia, and Patient Advocacy Ecosystem for the Efficient Development of Therapeutics
12:30 1:00 PM - Lunch Break
1:00 1:25 PM - Alex Kolevzon, MD
Predicting Treatment Response to Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
1:25 1:50 PM - Tim W. Yu, MD, PhD
Milestones on the Path Towards Genetic Interventions for Autism
1:50 2:00 PM - 10-Minute Break
2:00 2:25 PM - Jeffrey Neul, MD PhD
Rett Syndrome, from Gene Discovery to First Approved Treatment: Opportunities and Challenges for Future Clinical Trials
2:25 2:30 PM - 5-Minute Break
2:30 3:00 PM - All Speaker Panel
3:00 - 3:10 PM - Closing Remarks
About
Established in 1996, the conference brings together academic, parent, and community groups to participate in thoughtful and informative presentations. The goals of the event are to discuss recent advances in autism—the causes, symptoms, and current and future treatments.
The focus of the 2023 Advances in Autism Conference is Precision Medicine in Profound Autism.
International studies led by the Director of the Seaver Autism Center for Research and Treatment, Joseph D. Buxbaum, PhD, and colleagues, have identified more than 200 genes that, if changed, strongly contribute to autism. These discoveries also are showing that at least 25% of individuals with profound autism have genetic mutations.
Autism clinical researchers are now shifting their focus on treatments for autism. Rather than treating all autism as a single entity, we can now begin to look at genetically determined subtypes of autism, and consider treatments that are tailored to the genetic subtype. This approach, called precision medicine, has revolutionized cancer treatment, and will revolutionize the treatment of profound autism.
Attend the conference to learn how researchers are identifying genetic mutations in autism, how the mutations lead to biologically-determined subtypes of autism, and how preclinical research and clinical research are developing and testing new treatments for these subtypes. The interactions between academic scientists, families and advocacy groups, and industry partners will also be discussed, as precision medicine requires input from all these groups.
Online Conference Portal
Reserve Tickets Online
Agenda
10:30 10:40 AM - Opening Remarks
10:40 11:05 AM - Joseph D. Buxbaum, PhD
Genetics-First Approaches to Therapeutics in Autism
11:05 11:30 AM - Nael Nadif Kasri, PhD
Modelling Neurodevelopmental Disorders in a Dish
11:30 11:40 AM - 10-Minute Break
11:40 AM 12:05 PM - Bill Polvino, MD
New Drug Development in the Pharmaceutical Industry
12:05 12:30 PM - Rachel Groth, PhD
Building a Pharmaceutical Industry, Academia, and Patient Advocacy Ecosystem for the Efficient Development of Therapeutics
12:30 1:00 PM - Lunch Break
1:00 1:25 PM - Alex Kolevzon, MD
Predicting Treatment Response to Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
1:25 1:50 PM - Tim W. Yu, MD, PhD
Milestones on the Path Towards Genetic Interventions for Autism
1:50 2:00 PM - 10-Minute Break
2:00 2:25 PM - Jeffrey Neul, MD PhD
Rett Syndrome, from Gene Discovery to First Approved Treatment: Opportunities and Challenges for Future Clinical Trials
2:25 2:30 PM - 5-Minute Break
2:30 3:00 PM - All Speaker Panel
3:00 - 3:10 PM - Closing Remarks
